Profile: Fred Hassan, pharma titan, gooseberry picker and secret geography geek
This article was originally published in Scrip
Executive Summary
Fred Hassan, partner and managing director at Warburg Pincus, was CEO of Schering-Plough until 2009 when it merged with Merck & Co. He then joined Warburg Pincus and was chairman of eye care firm Bausch + Lomb until its sale in 2013. Before joining Schering-Plough in 2003, Mr Hassan was chairman and CEO of Pharmacia, and he previously held senior executive positions at Wyeth and Sandoz.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.